Logo

Anavex Reports Results of ANAVEX 2-73 (blarcamesine) in P-III (AVATAR) Trial for the Treatment of Rett Syndrome

Share this
Anavex Reports Results of ANAVEX 2-73 (blarcamesine) in P-III (AVATAR) Trial for the Treatment of Rett Syndrome

Anavex Reports Results of ANAVEX 2-73 (blarcamesine) in P-III (AVATAR) Trial for the Treatment of Rett Syndrome

Shots:

  • The P-III (AVATAR) trial evaluates the safety, tolerability, PK, and efficacy of ANAVEX 2-73 (30mg) vs PBO in 36 female patients with Rett syndrome for 7wks.
  • The trial met 1EPs & 2EPs i.e., improvement of RSBQ AUC (72.2% vs 38.5%); emotional behavior symptoms (ADAMS) (52.9% vs 8.3%); c CGI-I response (72.2% vs 38.5%), reductions in Rett syndrome symptoms with changes in biomarkers (GABA & L-AAA), was well tolerated. The results were consistent with the known safety profile of ANAVEX 2-73 
  • ANAVEX 2-73 has received FTD, RPDD & ODD from the US FDA for Rett syndrome. The therapy is being evaluated in the P-II/III (EXCELLENCE) study for the same indication in patients aged 5 to 17yrs.

Ref: Globe Newswire | Image: Anavex

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions